Company intelligence / Profile preview

Nepsone

Ownership: Private
Development stage: Preclinical

Overview

Nepsone ehf develops preclinical-stage small molecule drugs for skin diseases such as psoriasis, atopic dermatitis, and alopecia areata. Their approach leverages a novel neuroimmunology theory that implicates imbalances in the autonomic nervous system and neuropeptide activity as root causes of these diseases. No clinical results have been reported yet.

Therapeutic areas: Dermatology
Modalities: Small molecules / chemical drugs
Industry: Biotech

Partnerships

Grant from Tækniþróunarsjóður/Technology Development Fund of Rannís – The Icelandic Centre for Research

Beyond the preview

Go deeper on Nepsone.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nepsone.